Lumida
/CYTK
⌘K
Cytokinetics Inc

Cytokinetics Inc

CYTK
$73.77USD+0.20%+0.15 today

MARKET CAP

10.3B

P/E (TTM)

FWD P/E

DAY RANGE

$74 – $76

52W RANGE

$47
$88

AI Summary

Stalk
StalkMedium

CYTK remains under distribution pressure, with price rejecting at the 9- and 20-period EMAs and approaching its rising 200-day SMA. The active Post-Parabola Collapse pattern identifies mean-reversion eligibility, shifting the medium-term bias to bullish despite the short-term downtrend. However, tactical execution remains unfavorable until price can reclaim and accept above the short-term EMAs. Therefore, entries should be deferred ("Stalk") around the 200-day SMA support, awaiting a clear reversal signal.

  • Q2 revenue of $28.6M outperforms $17.1M forecast; MYQORZO nets $25.3M with 40% share
  • Cash and investments of ~$1.7B fund commercialization through early 2026
  • Q2 R&D spending rose to $112.6M, straining cash runway
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$70.4M$94.6M$7.5M$18.5M$88.0M
YoY %+26.2%+34.3%-92.0%+145.3%+376.6%
P / Sales49.8x42.1x1078.3x285.1x86.7x
EV / Sales56.6x53.3x1224.1x363.2x109.0x
Gross Profit, Adj.$70.4M$94.6M$7.5M$18.5M$88.0M
YoY %+26.2%+34.3%-92.0%+145.3%+376.6%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit56.6x53.3x1224.1x363.2x109.0x
EBITDA, Adj.$-184.0M$-318.4M$-484.3M$-526.7M$-602.1M
YoY %-99.8%-73.0%-52.1%-8.8%-14.3%
Margin %-261.3%-336.6%-6431.8%-2851.1%-683.9%
EV / EBITDA-21.7x-15.8x-19.0x-12.7x-15.9x
EBIT$-186.3M$-324.2M$-496.2M$-536.2M$-612.3M
YoY %-98.3%-74.0%-53.1%-8.1%-14.2%
Margin %-264.5%-342.8%-6589.7%-2902.7%-695.4%
EV / EBIT-21.4x-15.5x-18.6x-12.5x-15.7x
Net Income$-215.3M$-389.0M$-526.2M$-589.5M$-785.0M
YoY %-69.2%-80.6%-35.3%-12.0%-33.2%
Net Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
EPS (GAAP)-$2.80-$4.33-$5.45-$5.26-$6.54
YoY %-42.1%-54.6%-25.9%+3.5%-24.3%